-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Since 2022, there have been constant news of the departure of executives in the pharmaceutical industry.
Among them, 30 executives have left in March alone, including the deputy general manager of Weili Medical, the general manager of Jiangzhong Pharmaceutical, and Kelun Pharmaceuticals.
industry directors,
etc.
In April, this wave of departures has become more and more turbulent, and a large number of executives from more than 10 pharmaceutical companies have announced their departure, including the chairman, vice president, and deputy general manager
.
Specifically, on April 18, Foci Pharmaceuticals issued an announcement stating that the board of directors received a written resignation report submitted by director Du Xiaozheng on April 15.
Du Xiaozheng applied for resignation as a director and a member of the strategy committee due to work reasons.
If you hold any position in the company and its subsidiaries, the resignation report will take effect when it is delivered to the board of directors
.
On the 18th, Jingfeng Pharmaceutical also issued an announcement saying that the company's board of directors recently received resignation reports submitted by Zheng Yuqun, Peng Long, and Liu Runhui
.
The reasons for resignation are personal reasons
.
After Peng Long and Liu Runhui resigned as independent directors, the number of independent directors of the company is less than one-third of the total number of directors.
Effective after independent directors
.
On April 15, Xinbang Pharmaceutical issued an announcement on the company's personnel changes.
The announcement stated that the board of directors received a written resignation report from the chairman of the board of directors on April 13.
Ann Huailuo applied for his resignation as chairman, director, chairman of the eighth session of the board of directors due to personal reasons.
Convenor of the Strategy Committee of the Board of Directors and member of the Remuneration and Appraisal Committee
.
On April 13, Lanfan Medical announced that Sun Chuanzhi, vice president and chief financial officer, resigned due to personal reasons, and the departure time was April 12, 2022
.
After his resignation, Cui Yuntao will assume the positions of vice president and chief financial officer on April 12, 2022
.
According to the data, Mr.
Cui Yuntao, the newly appointed vice president and chief financial officer of Lanfan Medical, used to be the director and general manager of the financial management department of Peking University Founder Group Co.
,
Ltd.
On April 12, Hengrui Pharmaceutical announced that the board of directors of the company has recently received a resignation report from Zou Jianjun, the company's deputy general manager.
After resigning from the above-mentioned position for personal reasons, Zou Jianjun will no longer hold any position in the company, and the relevant work he is responsible for has been carried out.
handover
.
Hengrui Medicine also announced that Zhang Xiaojing was appointed as Hengrui Medicine's Deputy General Manager and Chief Medical Officer (Oncology), and Wang Quanren was appointed as Hengrui Medicine's Deputy General Manager
.
On the 12th, Rongchang Bio also announced that the board of directors recently received a written resignation report from Ms.
Yu Shanshan, an independent director of the company
.
Due to personal job changes, he voluntarily applied to resign as an independent director of the company, a member of the audit committee, and chairman of the remuneration and appraisal committee.
After the resignation takes effect, he will no longer hold any positions in the company
.
According to the "Rules for Independent Directors of Listed Companies" and the "Articles of Association", Ms.
Yu Shanshan's resignation will take effect after the election of a new independent director at the company's general meeting of shareholders
.
On April 11, Guangyuyuan announced that Shi Jing, an employee supervisor of the seventh session of the Supervisory Committee, no longer served as an employee representative supervisor due to work reasons
.
At the same time, the company elected Li Na as the employee representative supervisor of the seventh board of supervisors, which is consistent with the tenure of the seventh board of supervisors
.
On April 8, Ruikang Pharmaceutical announced that Mr.
Luan Tonghui and Mr.
Wei Qingyi applied to resign as deputy general managers due to personal reasons, and will no longer hold other positions in the company after their resignation
.
Due to the needs of the company's operation and management, it has been nominated by the general manager, and upon deliberation and approval at the 20th meeting of the fourth board of directors, it was agreed to appoint Mr.
Chen Jinghui and Ms.
Shi Zhongqin as deputy general managers
.
.
.
.
From the above point of view, the industry predicts that in the market environment such as medical reform and centralized procurement, the flow of executives in the pharmaceutical industry will still be very frequent in the future
.
Judging from the positions that these executives have left, the general manager, deputy general manager, and vice president may still be the focus of the flow
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Among them, 30 executives have left in March alone, including the deputy general manager of Weili Medical, the general manager of Jiangzhong Pharmaceutical, and Kelun Pharmaceuticals.
industry directors,
etc.
In April, this wave of departures has become more and more turbulent, and a large number of executives from more than 10 pharmaceutical companies have announced their departure, including the chairman, vice president, and deputy general manager
.
Specifically, on April 18, Foci Pharmaceuticals issued an announcement stating that the board of directors received a written resignation report submitted by director Du Xiaozheng on April 15.
Du Xiaozheng applied for resignation as a director and a member of the strategy committee due to work reasons.
If you hold any position in the company and its subsidiaries, the resignation report will take effect when it is delivered to the board of directors
.
On the 18th, Jingfeng Pharmaceutical also issued an announcement saying that the company's board of directors recently received resignation reports submitted by Zheng Yuqun, Peng Long, and Liu Runhui
.
The reasons for resignation are personal reasons
.
After Peng Long and Liu Runhui resigned as independent directors, the number of independent directors of the company is less than one-third of the total number of directors.
Effective after independent directors
.
On April 15, Xinbang Pharmaceutical issued an announcement on the company's personnel changes.
The announcement stated that the board of directors received a written resignation report from the chairman of the board of directors on April 13.
Ann Huailuo applied for his resignation as chairman, director, chairman of the eighth session of the board of directors due to personal reasons.
Convenor of the Strategy Committee of the Board of Directors and member of the Remuneration and Appraisal Committee
.
On April 13, Lanfan Medical announced that Sun Chuanzhi, vice president and chief financial officer, resigned due to personal reasons, and the departure time was April 12, 2022
.
After his resignation, Cui Yuntao will assume the positions of vice president and chief financial officer on April 12, 2022
.
According to the data, Mr.
Cui Yuntao, the newly appointed vice president and chief financial officer of Lanfan Medical, used to be the director and general manager of the financial management department of Peking University Founder Group Co.
,
Ltd.
On April 12, Hengrui Pharmaceutical announced that the board of directors of the company has recently received a resignation report from Zou Jianjun, the company's deputy general manager.
After resigning from the above-mentioned position for personal reasons, Zou Jianjun will no longer hold any position in the company, and the relevant work he is responsible for has been carried out.
handover
.
Hengrui Medicine also announced that Zhang Xiaojing was appointed as Hengrui Medicine's Deputy General Manager and Chief Medical Officer (Oncology), and Wang Quanren was appointed as Hengrui Medicine's Deputy General Manager
.
On the 12th, Rongchang Bio also announced that the board of directors recently received a written resignation report from Ms.
Yu Shanshan, an independent director of the company
.
Due to personal job changes, he voluntarily applied to resign as an independent director of the company, a member of the audit committee, and chairman of the remuneration and appraisal committee.
After the resignation takes effect, he will no longer hold any positions in the company
.
According to the "Rules for Independent Directors of Listed Companies" and the "Articles of Association", Ms.
Yu Shanshan's resignation will take effect after the election of a new independent director at the company's general meeting of shareholders
.
On April 11, Guangyuyuan announced that Shi Jing, an employee supervisor of the seventh session of the Supervisory Committee, no longer served as an employee representative supervisor due to work reasons
.
At the same time, the company elected Li Na as the employee representative supervisor of the seventh board of supervisors, which is consistent with the tenure of the seventh board of supervisors
.
On April 8, Ruikang Pharmaceutical announced that Mr.
Luan Tonghui and Mr.
Wei Qingyi applied to resign as deputy general managers due to personal reasons, and will no longer hold other positions in the company after their resignation
.
Due to the needs of the company's operation and management, it has been nominated by the general manager, and upon deliberation and approval at the 20th meeting of the fourth board of directors, it was agreed to appoint Mr.
Chen Jinghui and Ms.
Shi Zhongqin as deputy general managers
.
.
.
.
From the above point of view, the industry predicts that in the market environment such as medical reform and centralized procurement, the flow of executives in the pharmaceutical industry will still be very frequent in the future
.
Judging from the positions that these executives have left, the general manager, deputy general manager, and vice president may still be the focus of the flow
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
